gpt-dict.com

維生素 E Vitamin E × 非酒精性脂肪肝病 / 非酒精性脂肪肝炎（NAFLD/NASH）

結論：證據支持但有警示

L11 明確建議 publish_with_warning — honor L11 recommendation (B10 fix)

B 🟡 B 初步證據 附警語發布 ⚠️ medium — moderate promotional content
⚠️ 標記 🇹🇼 台灣在地警示 💊 檢驗 / 藥物交互作用

⚖️

評分透明度

所有分數由 7 層證據引擎計算，過程公開可查
原始分數 0.69
D
C
B
A
S
← 反證據 / 無效有效 / 強證據 →
最終評級
B · 附警語發布
信心度
85%
證據方向一致性高
證據層級
E2
多篇高品質統合分析（≥2 篇一致）

各層「支持此療效」的程度

分數越低＝該層越不支持
L1 Examine國際基準
0.50
L3 機轉生理合理性
0.65
L11 AI 複核獨立判讀
0.65
L2 PubMed原始文獻
0.75
L5 臨床機構權威立場
0.75
不支持 中性 / 混合 支持
▸查看完整決策路徑（audit trail）
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.69
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (2 篇 > 0 negative)
  4. tier_strict_requirement_check — Tier 條件達標，未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis (PIVENS)
PMID: 20427778 2010 RCT (double-blind) n = 247
結論：Vitamin E achieved primary endpoint in 43% vs 19% placebo (p=0.001); improved steatosis, lobular inflammation, ballooning, and ALT/AST; fibrosis scores did not improve over placebo. Pioglitazone 34% vs 19% (p=0.04, did not meet pre-specified significance threshold).
🟢 高品質 政府資助 效應量：Absolute risk difference +24% for histologic improvement (RR ~2.3 vs placebo); NNT ~4
前往 PubMed
Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial
PMID: 21521847 2011 RCT (double-blind) n = 173
結論：Primary endpoint not met: vitamin E 26% vs placebo 17% (p=0.26). However, vitamin E significantly improved hepatocellular ballooning (p=0.006) and NAFLD activity score (p=0.02); among children with NASH at baseline, resolution rate 58% (Vit E) vs 28% (placebo) (p=0.006).
🟢 高品質 政府資助 效應量：Primary ALT outcome NS; histologic NASH resolution +30% absolute vs placebo
前往 PubMed
Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial (Bril et al.)
PMID: 31332029 2019 RCT (double-blind) n = 105
結論：Vitamin E monotherapy did NOT meet primary endpoint vs placebo (31% vs 19%, p=0.26). Combination Vit E + pioglitazone superior to placebo (54% vs 19%, p=0.003). NASH resolution: combo 43% vs placebo 12%; Vit E alone intermediate. No fibrosis improvement in any arm.
🟢 高品質 學術資助 效應量：Vit E alone: absolute +12% (NS); Combo: absolute +35% (significant)
前往 PubMed
The Effect of Vitamin E Supplementation on Serum Aminotransferases in Non-Alcoholic Fatty Liver Disease (NAFLD): A Systematic Review and Meta-Analysis
PMID: 37686767 2023 統合分析 n = 794
結論：Vitamin E significantly reduced ALT (MD -13.06 IU/L, 95% CI -19.17 to -6.96) and AST vs control. Subgroup effects in both Asian (ALT MD -6.99) and non-Asian (MD -9.57) populations. Heterogeneity moderate; histology not pooled.
學術資助 效應量：ALT MD -13.06 IU/L (95% CI -19.17 to -6.96)
前往 PubMed
Systematic review with meta-analysis: The effect of vitamin E supplementation in adult patients with non-alcoholic fatty liver disease (Vadarlis et al.)
PMID: 32810309 2021 統合分析
結論：Vitamin E reduced ALT by 7.37 IU/L and AST by 5.71 IU/L vs control; improved histologic NAFLD activity score (esp. in NASH subset); also reduced LDL-C, FBG, and leptin. Authors conclude Vit E can be considered a treatment option for NASH but not NAFLD broadly.
學術資助 效應量：ALT MD -7.37 IU/L; AST MD -5.71 IU/L
前往 PubMed
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease (Rinella et al.)
PMID: 36727674 2023 Other
結論：AASLD 2023 issues a conditional recommendation that vitamin E 800 IU/day may be considered in non-diabetic adults with biopsy-proven NASH, citing PIVENS as the anchor evidence. Notes lack of antifibrotic benefit, no data in cirrhosis, and uncertainty re: long-term safety (prostate cancer signal in SELECT, hemorrhagic stroke signal). Not recommended for NAFLD without histologic NASH, for diabetics, or for children outside research settings.
🟢 高品質 學術資助
前往 PubMed

L4a US FDA
謹慎
Some scientific evidence suggests that consumption of antioxidant vitamins may reduce the risk of certain forms of cancer. However, FDA has determined that this evidence is limited and not conclusive. 來源↗
L4b EU EFSA
謹慎
The effect on blood clotting and associated increased risk of bleeding is considered as the critical effect to establish an UL for vitamin E. ... The ULs for vitamin E from all dietary sources, which were previously established by the Scientific Committee on Food, are retained for all population groups 來源↗
L4c UK NHS
謹慎
You should be able to get all the vitamin E you need from your diet. Taking 540mg (800 IU) or less a day of vitamin E supplements is unlikely to cause any harm. If you take vitamin E supplements, do not take too much as this could be harmful. 來源↗
L4d TW TFDA / 衛福部
謹慎
其維生素E之總含量不得高於400I.U.（268mg d-α-tocopherol） 來源↗
L4e WHO
謹慎
Vitamin E and C supplementation is not recommended for pregnant women to improve maternal and perinatal outcomes. 來源↗

L5a NIH Office of Dietary Supplements
謹慎
Clinical trials have not provided evidence that routine use of vitamin E supplements prevents cardiovascular disease or reduces its morbidity and mortality. 來源↗
L5b Mayo Clinic
謹慎
Vitamin E is not safe for everyone. For instance, it's not recommended for people with serious liver scarring or type 2 diabetes. 來源↗
L5c Cleveland Clinic
支持
You may also need to take vitamin E and thiazolidinediones (drugs used to treat diabetes, such as Actos® and Avandia®) in specific instances. 來源↗
L5d Harvard Health
支持
the two best drug options affirmed by the American Association for the Study of Liver Diseases for biopsy-proven NASH are vitamin E (an antioxidant) and pioglitazone (used to treat diabetes) 來源↗
L5e Specialty Society (condition-mapped)
支持
Vitamin E (α-tocopherol) administered at daily dose of 800 IU/day improves liver histology in non-diabetic adults with biopsy-proven NASH and therefore it should be considered as a first-line pharmacotherapy for this patient population. 來源↗

PTT · Dcard · Mobile01 彙整自公開論壇討論，非統計抽樣，僅反映社群風向。
廣告 / 業配密度 中度
低中高
📍立場總覽

台灣社群幾乎沒有「維生素E 專門用於 NAFLD/NASH」的真實鄉民實測串；脂肪肝討論串（regimen/Health/WomenTalk）主軸壓倒性集中在減重、少油糖、運動，保健品話題多談魚油、薑黃、奶薊草，維他命E 多以「吃堅果補E助脂肪代謝」的轉貼新聞片段帶過。維他命E 自身的討論串則集中在劑量與脂溶性蓄積風險（建議每日上限約 400IU、>1000mg 視為不安全），鄉民理性派常引用過量恐增出血性中風、攝護腺癌風險。PIVENS／AASLD 800IU 對非糖尿病活檢確診 NASH 的證據幾乎只出現在商業健康媒體（TVBS 健康2.0、元氣網、Heho、健保品電商），未轉化為社群一手經驗，整體屬低訊號、無共識。

💬社群實感

無共識（針對 NAFLD/NASH 幾乎無一手實測心得；脂肪肝社群討論以減重/飲食/魚油為主，維他命E 多為轉貼新聞而非親身經驗）

破解迷思 社群最常見的 4 個誤解
✓
事實把「吃堅果補維他命E 助脂肪代謝」的飲食轉貼新聞，誤解為維他命E 補充品可治療/逆轉脂肪肝（真正有證據的是 AASLD 對非糖尿病、無肝硬化、活檢確診 NASH 才建議 800IU/日，非一般脂肪肝通用）
✓
事實誤以為維他命E 是脂肪肝的常規保健選項，忽略其屬處方等級高劑量、需醫師評估，且糖尿病患不適用
✓
事實脂溶性維生素「多吃保養無妨」的迷思（實為會蓄積體內，高劑量恐增出血性中風與攝護腺癌風險）
✓
事實把改善 ALT/發炎指數誤等同於治癒脂肪肝或可取代減重與飲食控制
🩹 社群通報的副作用
  • 高劑量恐增出血性中風風險（社群常引述約 +22%）
  • 高劑量與男性攝護腺癌風險的疑慮
  • 干擾凝血、與抗凝血劑併用易出血
  • 過量蓄積：噁心、腹瀉、視力模糊、肌肉無力（多為一般過量警語而非脂肪肝使用者實測回報）

查看代表討論串 ↗

L10a · 廠商行銷話術 行銷語言
💬 通路如何宣傳

天然型維生素E，吸收率更佳

代表來源 ↗
L10b · TFDA 法定身份 官方認定

超過 268 mg α-T.E.（400 I.U.）就要作為藥品申請

來源 ↗

  • 減重（飲食調整與運動）
  • 地中海飲食型態
  • 減少或戒除酒精
✓ PMID 100% 反查全部經 NCBI Entrez 驗證
🔬 6 篇 L2 文獻 經多層 sub-agent 獨立評估
🇹🇼 含台灣社群分析L10c PTT / Dcard / Mobile01
aggregated_at: 2026-06-01 claim_version: v30 engine_version: v1.0 claim_id: CLM-COND-nafld-INT-vitamin-e-001
查看 ClaimReview 結構化資料 (JSON-LD) 
{
  "@context": "https://schema.org",
  "@type": "ClaimReview",
  "url": "https://gpt-dict.com/claim/CLM-COND-nafld-INT-vitamin-e-001/",
  "datePublished": "2026-06-01",
  "author": {
    "@type": "Organization",
    "name": "gpt-dict.com",
    "url": "https://gpt-dict.com"
  },
  "claimReviewed": "維生素 E能改善非酒精性脂肪肝病 / 非酒精性脂肪肝炎（NAFLD/NASH）",
  "inLanguage": "zh-TW",
  "itemReviewed": {
    "@type": "Claim",
    "appearance": []
  },
  "reviewRating": {
    "@type": "Rating",
    "ratingValue": 3,
    "bestRating": 5,
    "worstRating": 1,
    "alternateName": "🟡 B 初步證據"
  }
}